Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The Future of ER+/HER2- Metastatic Breast Cancer Therapy: Beyond PI3K Inhibitors.

Anticancer research - 1 Sept 2020

Stravodimou Athina, Voutsadakis Ioannis A

Abstract excerpt

Most breast cancers express the estrogen receptor (ER) receptor and are negative for the human epidermal growth factor receptor 2 (HER2) receptor. ER+/HER2- cancers are treated with hormone-based therapies in the adjuvant setting and derive significant survival benefit from these therapies in the metastatic setting. However, hormone resistance develops in most metastatic patients. An increased understanding of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Apoptosis
Share to Breast Neoplasms

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Resistance, Neoplasm

Share to Phosphatidylinositol 3-Kinases

Share to Receptor, ErbB-2

Share to Receptors, Estrogen

Share to Receptors, Fibroblast Growth Factor

Source

Identifiers

PMID: 32878771
DOI: 10.21873/anticanres.14486

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The Future of ER+/HER2- Metastatic Breast Cancer Therapy: Beyond PI3K Inhibitors.PMID 32878771Read ↗

Targeted therapies for ER+/HER2- metastatic breast cancerSemantic proximity Read ↗

Advances in EGFR/HER2-directed clinical research on breast cancer.Semantic proximity Read ↗

How I treat endocrine-dependent metastatic breast cancer.Semantic proximity Read ↗

The Present and Future of Clinical Management in Metastatic Breast CancerSemantic proximity Read ↗

Molecular Mechanisms and Therapeutic Strategies to Overcome Resistance to Endocrine Therapy and CDK4/6 Inhibitors in Advanced ER+/HER2- Breast CancerSemantic proximity Read ↗

Targeted and cytotoxic inhibitors used in the treatment of breast cancerSemantic proximity Read ↗

A Comprehensive Review of HER2 in Cancer Biology and TherapeuticsSemantic proximity Read ↗

A Comprehensive Review of HER2 in Cancer Biology and TherapeuticsSemantic proximity Read ↗

Molecular Targeting the Human Epidermal Growth Factor Receptor-2 (HER2) Genes Across Various CancerSemantic proximity Read ↗

Metastatic ER+ Breast Cancer: Mechanisms of Resistance and Future Therapeutic ApproachesSemantic proximity Read ↗

Molecular Targeting of the Human Epidermal Growth Factor Receptor-2 (HER2) Genes across Various CancersSemantic proximity Read ↗

Divide and Conquer—Targeted Therapy for Triple-Negative Breast CancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.